Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
ACS Chem Neurosci ; 10(3): 1380-1389, 2019 03 20.
Article in English | MEDLINE | ID: mdl-30375852

ABSTRACT

Arylguanidines, depending upon their aromatic substitution pattern, display varying actions at 5-HT3 receptors (e.g., partial agonist, agonist, superagonist). Here, we demonstrate that conformational constraint of these agents as dihydroquinazolines (such as A6CDQ; 1) results in their conversion to 5-HT3 receptor antagonists. We examined the structure-activity relationships of 1. Replacement/removal of any of the guanidinium nitrogen atoms of 1 resulted in decreased affinity. All three nitrogen atoms of 1 are necessary for optimal binding affinity at 5-HT3 receptors. Introduction of substituents as small as an N2-methyl group abolishes affinity. The results are consistent with homology modeling/docking studies and binding data from site-directed mutagenesis studies. Introducing a "methylene bridge" to the arylguanidine structure, regardless of its functional activity, results in a 5-HT3 receptor antagonist.


Subject(s)
Guanidines/metabolism , Methane/metabolism , Receptors, Serotonin, 5-HT3/metabolism , Serotonin 5-HT3 Receptor Antagonists/metabolism , Animals , Dose-Response Relationship, Drug , Female , Guanidines/chemistry , HEK293 Cells , Humans , Methane/chemistry , Protein Binding/physiology , Protein Structure, Secondary , Protein Structure, Tertiary , Receptors, Serotonin, 5-HT3/chemistry , Serotonin 5-HT3 Receptor Antagonists/chemistry , Xenopus
2.
ACS Chem Neurosci ; 7(11): 1565-1574, 2016 11 16.
Article in English | MEDLINE | ID: mdl-27533595

ABSTRACT

Introduction of minor variations to the substitution pattern of arylguanidine 5-hydroxytryptamine-3 (5-HT3) receptor ligands resulted in a broad spectrum of functionally-active ligands from antagonist to superagonist. For example, (i) introduction of an additional Cl-substituent(s) to our lead full agonist N-(3-chlorophenyl)guanidine (mCPG, 2; efficacy % = 106) yielded superagonists 7-9 (efficacy % = 186, 139, and 129, respectively), (ii) a positional isomer of 2, p-Cl analog 11, displayed partial agonist actions (efficacy % = 12), and (iii) replacing the halogen atom at the meta or para position with an electron donating OCH3 group or a stronger electron withdrawing (i.e., CF3) group resulted in antagonists 13-16. We posit based on combined mutagenesis, crystallographic, and computational analyses that for the 5-HT3 receptor, the arylguanidines that are better able to simultaneously engage the primary and complementary subunits, thus keeping them in close proximity, have greater agonist character while those that are deficient in this ability are antagonists.


Subject(s)
Guanidines/pharmacology , Serotonin 5-HT3 Receptor Agonists/pharmacology , Serotonin 5-HT3 Receptor Antagonists/pharmacology , Animals , Cell Line, Tumor , Dose-Response Relationship, Drug , Guanidines/chemical synthesis , Guanidines/chemistry , HEK293 Cells , Humans , Membrane Potentials/drug effects , Membrane Potentials/physiology , Mice , Models, Molecular , Molecular Structure , Mutation , Oocytes , Protein Binding , Receptors, Serotonin, 5-HT3/genetics , Receptors, Serotonin, 5-HT3/metabolism , Serotonin 5-HT3 Receptor Agonists/chemical synthesis , Serotonin 5-HT3 Receptor Agonists/chemistry , Serotonin 5-HT3 Receptor Antagonists/chemical synthesis , Serotonin 5-HT3 Receptor Antagonists/chemistry , Xenopus
3.
J Neurosci ; 34(43): 14210-8, 2014 Oct 22.
Article in English | MEDLINE | ID: mdl-25339735

ABSTRACT

Soluble ß-amyloid has been shown to regulate presynaptic Ca(2+) and synaptic plasticity. In particular, picomolar ß-amyloid was found to have an agonist-like action on presynaptic nicotinic receptors and to augment long-term potentiation (LTP) in a manner dependent upon nicotinic receptors. Here, we report that a functional N-terminal domain exists within ß-amyloid for its agonist-like activity. This sequence corresponds to a N-terminal fragment generated by the combined action of α- and ß-secretases, and resident carboxypeptidase. The N-terminal ß-amyloid fragment is present in the brains and CSF of healthy adults as well as in Alzheimer's patients. Unlike full-length ß-amyloid, the N-terminal ß-amyloid fragment is monomeric and nontoxic. In Ca(2+) imaging studies using a model reconstituted rodent neuroblastoma cell line and isolated mouse nerve terminals, the N-terminal ß-amyloid fragment proved to be highly potent and more effective than full-length ß-amyloid in its agonist-like action on nicotinic receptors. In addition, the N-terminal ß-amyloid fragment augmented theta burst-induced post-tetanic potentiation and LTP in mouse hippocampal slices. The N-terminal fragment also rescued LTP inhibited by elevated levels of full-length ß-amyloid. Contextual fear conditioning was also strongly augmented following bilateral injection of N-terminal ß-amyloid fragment into the dorsal hippocampi of intact mice. The fragment-induced augmentation of fear conditioning was attenuated by coadministration of nicotinic antagonist. The activity of the N-terminal ß-amyloid fragment appears to reside largely in a sequence surrounding a putative metal binding site, YEVHHQ. These findings suggest that the N-terminal ß-amyloid fragment may serve as a potent and effective endogenous neuromodulator.


Subject(s)
Amyloid beta-Peptides/pharmacology , Calcium/physiology , Conditioning, Psychological/physiology , Fear/physiology , Neuronal Plasticity/physiology , Presynaptic Terminals/physiology , Amino Acid Sequence , Amyloid beta-Peptides/physiology , Animals , Cell Line, Tumor , Conditioning, Psychological/drug effects , Fear/drug effects , Hippocampus/drug effects , Hippocampus/physiology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Molecular Sequence Data , Neuronal Plasticity/drug effects , Organ Culture Techniques , Presynaptic Terminals/drug effects
4.
Phys Rev E Stat Nonlin Soft Matter Phys ; 85(1 Pt 2): 015201, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22400610

ABSTRACT

The evanescent wave field outside an optical resonator is typically strongly directional when the shape deviates even very slightly from being perfectly circular or spherical. In this Rapid Communication we show that the tunneling mechanism underlying escape from such weakly deformed resonators can lead to emission patterns that look quite different to the corresponding internal mode. A direct short-wavelength analysis is not possible because the required complex ray data cannot be found due to the presence of natural boundaries. We show, however, that an approach based on perturbative approximation of the ray families successfully describes this phenomenon. In appropriate limits, the emission pattern allows one effectively to perform a direct observation of solutions of the one-dimensional Schrödinger equation in the complex plane.

5.
Protein Expr Purif ; 82(1): 6-10, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22100524

ABSTRACT

Conotoxin PrIIIE is a 22-amino acid peptide containing three disulfide bonds isolated from the venom of Conus parius Reeve. It is a non-competitive antagonist of the mammalian muscle nicotinic acetylcholine receptor (nAChR). We fused the PrIIIE to small ubiquitin-like modifier (SUMO) and expressed the fusion protein in an Escherichia coli strain with an oxidizing cytoplasm. We purified the fusion protein by immobilized metal affinity chromatography and further purified PrIIIE from cleaved SUMO using cation exchange chromatography. The yield of peptide was 1.5mg/L of culture. The recombinant peptide is functional, as demonstrated by two-electrode voltage clamp experiments. This system may prove valuable for future structure-function studies.


Subject(s)
Conotoxins/genetics , Conotoxins/isolation & purification , Conus Snail/genetics , Escherichia coli/genetics , Amino Acid Sequence , Animals , Chromatography, Affinity , Conotoxins/chemistry , Conotoxins/metabolism , Conus Snail/chemistry , Conus Snail/metabolism , Gene Expression , Mice , Molecular Sequence Data , Receptors, Nicotinic/metabolism , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/isolation & purification , Recombinant Fusion Proteins/metabolism , Xenopus
6.
J Biol Chem ; 286(39): 34373-81, 2011 Sep 30.
Article in English | MEDLINE | ID: mdl-21828053

ABSTRACT

Soluble ß-amyloid (Aß) resides in certain regions of the brain at or near picomolar concentration, rising in level during the prodromic stage of Alzheimer disease. Recently, we identified the homomeric α7 nicotinic acetylcholine receptor (α7-nAChR) as one possible functional target for picomolar Aß. This study was aimed at addressing which residues in α7-nAChRs potentially interact with Aß to regulate the presynaptic function of this receptor. Site-directed mutagenesis was carried out to study the key aromatic residues in the mouse α7-nAChR agonist-binding pocket. Mutations of tyrosine188 resulted in a decrease in activation of presynaptic α7-nAChRs by ACh and Aß but with no change in response to nicotine, indicating the critical role of Tyr-188 in presynaptic regulation by Aß. Coimmunoprecipitation additionally revealed direct binding of Aß to α7-nAChRs and to the Tyr-188 mutant receptor. In contrast, mutations of Tyr-195 in α7-nAChR led to decreased activation by nicotine without apparent effects on ACh- or Aß-induced responses. Agonist-induced responses of Tyr-93 mutant α7-nAChRs indicated possible interactions of nicotine and Aß with its hydroxyl group, but there was no change in presynaptic responses after mutation of Trp-149. All of the mutants were shown to be expressed on the plasma membrane using cell surface labeling. Together, these results directly demonstrate an essential role for the aromatic residue Tyr-188 as a key component in the agonist binding domain for the activation of α7-nAChRs by Aß.


Subject(s)
Amino Acids, Aromatic/metabolism , Amyloid beta-Protein Precursor/metabolism , Amyloid/metabolism , Receptors, Nicotinic/metabolism , Amino Acids, Aromatic/genetics , Amyloid/genetics , Amyloid beta-Protein Precursor/genetics , Animals , Cell Line , Mice , Mutagenesis, Site-Directed , Mutation, Missense , Peptide Mapping , Protein Structure, Tertiary , Receptors, Nicotinic/genetics , alpha7 Nicotinic Acetylcholine Receptor
7.
Biophys J ; 98(9): 1847-55, 2010 May 19.
Article in English | MEDLINE | ID: mdl-20441748

ABSTRACT

The serotonin 5-HT(3) receptor (5-HT(3)R) is a member of the Cys-loop ligand-gated ion channel family. We used a combination of site-directed mutagenesis, homology modeling, and ligand-docking simulations to analyze antagonist-receptor interactions. Mutation of E236, which is near loop C of the binding site, to aspartate prevents expression of the receptor on the cell surface, and no specific ligand binding can be detected. On the other hand, mutation to glutamine, asparagine, or alanine produces receptors that are expressed on the cell surface, but decreases receptor affinity for the competitive antagonist d-tubocurarine (dTC) 5-35-fold. The results of a double-mutant cycle analysis employing a panel of dTC analogs to identify specific points of interactions between the dTC analogs and E236 are consistent with E236 making a direct physical interaction with the 12 -OH of dTC. dTC is a rigid molecule of known three-dimensional structure. Together with previous studies linking other regions of dTC to specific residues in the binding site, these data allow us to define the relative spatial arrangement of three different residues in the ligand-binding site: R92 (loop D), N128 (loop A), and E236 (near loop C). Molecular modeling employing these distance constraints followed by molecular-dynamics simulations produced a dTC/receptor complex consistent with the experimental data. The use of the rigid ligands as molecular rulers in conjunction with double-mutant cycle analysis provides a means of mapping the relative positions of various residues in the ligand-binding site of any ligand-receptor complex, and thus is a useful tool for delineating the architecture of the binding site.


Subject(s)
Receptors, Serotonin, 5-HT3/chemistry , Receptors, Serotonin, 5-HT3/metabolism , Animals , Binding Sites , Cell Line, Tumor , Ligands , Mice , Molecular Dynamics Simulation , Mutagenesis, Site-Directed , Protein Structure, Tertiary , Receptors, Serotonin, 5-HT3/genetics , Serotonin 5-HT3 Receptor Antagonists , Tubocurarine/metabolism , Tubocurarine/pharmacology
8.
Biochemistry ; 46(5): 1194-204, 2007 Feb 06.
Article in English | MEDLINE | ID: mdl-17260949

ABSTRACT

The competitive antagonist d-tubocurarine (curare) has greater potency at mouse than at human 5-hydroxytryptamine 3A (5-HT3A) receptors, despite 84% amino acid sequence identity between the receptors. Within the ligand binding domain of this receptor are six loops (A-F). A previous report demonstrated that loop C of the 5-HT3A receptor contributed to differential potency between the receptors [Hope, A. G. et al. (1999) Mol. Pharmacol. 55, 1037-1043]. The present study tested the hypothesis that loop F plays a significant role in conferring interspecies curare potency differences. Wild-type, chimeric, and point mutant 5-HT3A receptors were expressed in Xenopus oocytes, and two-electrode voltage clamp electrophysiological recordings were performed. Our data suggest that loops C and F contribute to curare potency, given that the curare IC50's (concentration of drug that produces 50% inhibition of the response) for chimeric human receptors with substitutions of mouse residues in loop C (40.07 +/- 2.52 nM) or loop F (131.8 +/- 5.95 nM) were intermediate between those for the mouse (12.99 +/- 0.77 nM) and human (1817 +/- 92.36 nM) wild-type receptors. Two human point mutant receptors containing mouse receptor substitutions in loop F (H-K195E or H-V202I) had significantly lower curare IC50's than that of the human receptor. The human double mutant receptor, H-K195E,V202I, had the same curare IC50 (133.8 +/- 6.38 nM) as that of the human receptor containing all six loop F mouse substitutions. These results demonstrate that two loop F residues make a significant contribution in determining curare potency at the 5-HT3A receptor.


Subject(s)
Receptors, Serotonin/drug effects , Tubocurarine/pharmacology , Amino Acids , Animals , Binding Sites/genetics , Electrophysiology , Humans , Inhibitory Concentration 50 , Mice , Neuromuscular Nondepolarizing Agents/pharmacology , Oocytes , Point Mutation , Receptors, Serotonin/genetics , Receptors, Serotonin, 5-HT3 , Species Specificity , Transduction, Genetic , Xenopus
9.
Mol Pharmacol ; 70(2): 571-8, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16723497

ABSTRACT

The serotonin 5-HT(3) receptor (5-HT(3)R) is a member of the cys-loop ligand-gated ion channel family. We have used the combination of site-directed mutagenesis, homology modeling of the 5-HT(3)R extracellular domain, and ligand docking simulations as a way to map the architecture of the 5-HT(3)R ligand binding domain. Mutation of Phe226 in loop C of the binding site to tyrosine (F226Y) has no effect on the apparent affinity of the competitive antagonist d-tubocurarine (dTC) for the receptor. On the other hand, replacement of Asn128 in loop A of the binding site with alanine (N128A) increases the apparent affinity of dTC by approximately 10-fold. Double-mutant cycle analysis employing a panel of dTC analogs with substitutions at various positions to identify specific points of interactions between the dTC analogs and Asn128 suggests that Asn128 makes a direct interaction with the 2'N of dTC. Molecular modeling of the 5-HT(3)R extracellular domain using the antagonist-bound conformation of the Aplysia californica acetylcholine binding protein as a template followed by ligand docking simulations produces two classes of structures of the 5-HT(3)R/dTC complex; only one of these has the 2'N of dTC positioned at Asn128 and thus is consistent with the data from this study and previously published data. The use of the rigid dTC analogs as "molecular rulers" in conjunction with double-mutant cycle analysis of mutant receptors can allow the spatial mapping of the position of various residues in the ligand-binding site.


Subject(s)
Receptors, Serotonin, 5-HT3/chemistry , Tubocurarine/chemistry , Binding Sites , Cell Line , Humans , Ligands , Models, Molecular , Receptors, Serotonin, 5-HT3/metabolism , Structure-Activity Relationship , Tubocurarine/metabolism
10.
Mol Pharmacol ; 69(2): 407-10, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16293710

ABSTRACT

The members of the Cys-loop ligand-gated ion channel (LGIC) gene family play a major role in fast synaptic transmission, and these receptors represent an important class of targets for therapeutic agents. Each member of this gene family is a pentameric complex containing one or more different subunits, and a large number of subunits for each member have been identified. This large number of subunits could give rise to a bewildering array of possible subunit compositions and spatial arrangements within a single complex, not all of which may occur in vivo. Heterologous expression systems have been used to create specific combinations of individual subunits to mimic naturally occurring receptors. However, this approach is not without its problems. In this issue of Molecular Pharmacology, Groot-Kormelink et al. (page 559) describe a method for constructing "concatameric" receptors, in which five individual subunits are arranged in a predetermined order connected by a flexible linker. Expression of this construct results in the formation of receptors with a unique, predefined subunit stoichiometry and subunit arrangement within the receptor complex. Receptors formed from this construct are fully functional and have properties essentially identical to those formed from individual subunits. The application of this very general approach to other members of the LGIC family should markedly enhance our ability to understand how subunit composition influences receptor function, as well as provide a means for the expression of receptors of predefined subunit composition and arrangement as tools for the development of novel selective pharmacological and therapeutic agents.


Subject(s)
Ion Channel Gating , Receptors, Neurotransmitter/chemistry , Receptors, Neurotransmitter/genetics , Animals , Cysteine/chemistry , Humans , Protein Conformation , Protein Subunits/chemistry , Protein Subunits/genetics , Protein Subunits/metabolism , Receptors, Neurotransmitter/metabolism
11.
Mol Pharmacol ; 68(2): 365-71, 2005 Aug.
Article in English | MEDLINE | ID: mdl-15914697

ABSTRACT

The serotonin type 3 receptor (5-HT(3)R) is a member of the cys-loop ligand-gated ion channel (LGIC) superfamily. Like almost all membrane proteins, high-resolution structural data are unavailable for this class of receptors. We have taken advantage of the high degree of homology between LGICs and the acetylcholine binding protein (AChBP) from the freshwater snail Lymnea stagnalis, for which high-resolution structural data are available, to create a structural model for the extracellular (i.e., ligand-binding) domain of the 5-HT(3)R and to perform a series of ligand docking experiments to delineate the architecture of the ligand-binding site. Structural models were created using homology modeling with the AChBP as a template. Docking of the antagonist granisetron was carried out using a Lamarckian genetic algorithm to produce models of ligand-receptor complexes. Two energetically similar conformations of granisetron in the binding site were obtained from the docking simulations. In one model, the indazole ring of granisetron is near Trp90 and the tropane ring is near Arg92; in the other, the orientation is reversed. We used double-mutant cycle analysis to determine which of the two orientations is consistent with experimental data and found that the data are consistent with the model in which the indazole ring of granisetron interacts with Arg92 and the tropane ring interacts with Trp90. The combination of molecular modeling with double-mutant cycle analysis offers a powerful approach for the delineation of the architecture of the ligand-binding site.


Subject(s)
Granisetron/chemistry , Granisetron/metabolism , Receptors, Serotonin, 5-HT3/chemistry , Receptors, Serotonin, 5-HT3/metabolism , Animals , Binding Sites/physiology , Cell Line , Cell Line, Tumor , Dose-Response Relationship, Drug , Humans , Ligands , Mice , Protein Structure, Secondary/physiology , Serotonin 5-HT3 Receptor Antagonists
12.
Neuropharmacology ; 43(3): 367-73, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12243766

ABSTRACT

d-Tubocurarine is a potent competitive antagonist of both the muscle-type nicotinic acetylcholine receptor (AChR) and the serotonin type-3 receptor (5HT(3)R). We have previously used a series of structural analogs of d-tubocurarine to demonstrate that the ligand-binding domains of both receptors share common structural features. We have now extended these studies to examine the interaction of a series of d-tubocurarine analogs with 5HT(3)Rs containing mutations at either of two residues within the ligand-binding domain of the receptor (W90F and R92A). The W90F mutation results in an approximately 2-4-fold decrease in the affinity of the analogs relative to wild-type receptors, while the R92A results in an approximately 8-10-fold increase in affinity. However, since the effect of a given mutation is more or less equivalent for all analogs, neither residue W90 nor R92 is likely to make a specific interaction with d-tubocurarine itself. Rather, these two residues are likely to play a role in determining both the geometry of the binding site, as well as the overall environment that a ligand encounters in the binding site.


Subject(s)
Neuromuscular Nondepolarizing Agents/pharmacology , Receptors, Serotonin/drug effects , Receptors, Serotonin/genetics , Serotonin Antagonists/pharmacology , Tubocurarine/analogs & derivatives , Tubocurarine/pharmacology , Algorithms , Cloning, Molecular , DNA, Complementary , Humans , Ligands , Mutation , Receptors, Serotonin, 5-HT3 , Transfection , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...